309. DEVELOPMENT AND VALIDATION OF AN ELISA FOR HIGH TEMPERATURE REQUIREMENT FACTOR A3 (HtrA3): EARLY DETECTION OF PREECLAMPSIA
K. Dynon A and G. Nie AImplantation and Placental Development Group, Prince Henry’s Institute of Medical Research, Clayton, VIC, Australia.
Reproduction, Fertility and Development 22(9) 109-109 https://doi.org/10.1071/SRB10Abs309
Published: 6 September 2010
Abstract
Preeclampsia (PE) is a multisystemic condition in pregnant women that can be life threatening for both mother and baby. PE is a hypertensive disorder that develops concurrently with proteinuria after 20 weeks of gestation. Abnormal placental development during early pregnancy precedes the onset of PE later in gestation. Early diagnosis of PE is essential to reduce PE-related mortality and morbidity. To date there is no clinically useful biochemical diagnostic method that can detect PE during early pregnancy. Our laboratory discovered and cloned the serine protease HtrA3 and has shown that HtrA3 protein levels are intimately involved in placentation (1). Persistently high serum levels of HtrA3 are detected at the end of the first trimester in pregnant women who subsequently develop PE, suggesting that monitoring HtrA3 in maternal blood during early pregnancy may identify women at risk for PE. To develop monoclonal antibodies specific for HtrA3; and to develop an enzyme-linked immunosorbent assay (ELISA) to detect HtrA3 in human sera. Monoclonal antibodies were generated against full length human HtrA3 and small HtrA3 peptides and tested on recombinant HtrA3, human sera and first trimester decidual and villous tissues using western blot, immunoprecipitation and Amplified luminescent proximity homogeneous assay (Alpha)LISA technology. Three antibody pairs were identified that detected either short and/or long isoforms of HtrA3 in sera and placental tissues. Recombinant HtrA3 was detected by AlphaLISA and higher levels of HtrA3 were detected in serum of PE women compared to gestation-matched controls in preliminary testing. These antibody pairs can now be used for the development of specific and high throughput assays. The AlphaLISA will then be used to validate that abnormal serum HtrA3 levels during early pregnancy can predict preeclampsia.
(1) Nie et al, (2006) Biol Reprod 74, 366–374.
